Nuvalent, Inc. (NUVL)
101.24
-1.08
(-1.06%)
USD |
NASDAQ |
May 21, 16:00
101.18
-0.06
(-0.06%)
After-Hours: 19:59
Nuvalent Research and Development Expense (TTM) : 316.16M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Cogent Biosciences, Inc. | 277.48M |
| Neurocrine Biosciences, Inc. | 1.049B |
| BioMarin Pharmaceutical, Inc. | 721.03M |
| Kodiak Sciences, Inc. | 187.28M |
| Olema Pharmaceuticals, Inc. | 176.30M |